Michael J. Dunn - Mar 20, 2023 Form 4 Insider Report for CalciMedica, Inc. /DE/ (CALC)

Role
President and COO
Signature
By John Dunn, Attorney-in-Fact
Stock symbol
CALC
Transactions as of
Mar 20, 2023
Transactions value $
$0
Form type
4
Date filed
3/22/2023, 08:47 PM
Next filing
May 10, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CALC Employee Stock Option (right to buy) Award +11.8K 11.8K Mar 20, 2023 Common Stock 11.8K $1.39 Direct F1, F2
transaction CALC Employee Stock Option (right to buy) Award +22.8K 22.8K Mar 20, 2023 Common Stock 22.8K $2.44 Direct F1, F3, F4
transaction CALC Employee Stock Option (right to buy) Award +8.64K 8.64K Mar 20, 2023 Common Stock 8.64K $2.44 Direct F4, F5, F6
transaction CALC Employee Stock Option (right to buy) Award +23.6K 23.6K Mar 20, 2023 Common Stock 23.6K $6.60 Direct F4, F7, F8
transaction CALC Employee Stock Option (right to buy) Award +7.92K 7.92K Mar 20, 2023 Common Stock 7.92K $7.99 Direct F4, F9, F10
transaction CALC Employee Stock Option (right to buy) Award +13.1K 13.1K Mar 20, 2023 Common Stock 13.1K $7.99 Direct F1, F4, F11
transaction CALC Employee Stock Option (right to buy) Award +7.92K 7.92K Mar 20, 2023 Common Stock 7.92K $7.99 Direct F4, F9, F10
transaction CALC Employee Stock Option (right to buy) Award +1.32K 1.32K Mar 20, 2023 Common Stock 1.32K $10.42 Direct F1, F4, F12
transaction CALC Employee Stock Option (right to buy) Award +1.95K 1.95K Mar 20, 2023 Common Stock 1.95K $10.42 Direct F1, F4, F13
transaction CALC Employee Stock Option (right to buy) Award +24.7K 24.7K Mar 20, 2023 Common Stock 24.7K $17.34 Direct F4, F14, F15
transaction CALC Employee Stock Option (right to buy) Award +847 847 Mar 20, 2023 Common Stock 847 $17.34 Direct F4, F14, F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Immediately exercisable.
F2 Received in exchange for a stock option to acquire 408,402 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
F3 Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F4 Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
F5 25% of the shares subject to the option vested on April 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.
F6 Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F7 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.
F8 Received in exchange for a stock option to acquire 819,064 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F9 Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
F10 Received in exchange for a stock option to acquire 274,848 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F11 Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F12 Received in exchange for a stock option to acquire 45,955 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F13 Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F14 Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
F15 Received in exchange for a stock option to acquire 859,280 shares of common stock of CalciMedica pursuant to the Merger Agreement.
F16 Received in exchange for a stock option to acquire 29,420 shares of common stock of CalciMedica pursuant to the Merger Agreement.